title: [Prescription of psychotropic drugs in paediatry: approved indications and therapeutic perspectives].
abstract: In France, psychotropic drugs may be classified in four categories according to their official data. The first category corresponds to psychotropic drugs with an approved indication available in paediatry. Theyare old agents (e.g. haloperidol, amitriptyline, benzodiazepines...) with the exception of methylphenidate (hyperactivity). The second one corresponds to pharmacological agents approved for some indications obtained with adults but not for a1l (i.e. restricted indication: e.g. sertraline approved in paediatry only for OCD but not for depression, risperidone approved only for the treatment of disruptive behaviors in children with subaverage IQs). For the third category, the psychotropic agent is either contraindicated or unadvised under the age of 15 or 18 years, by lack of data (e.g. most of SSRI or atypical antipsychotic drugs). For the last category, official data available in brief summaries offer no information on paediatric use and consequently their administration does not appear possible. Up to now, no approved use has been delivered to injection route (IM or IV) in France, except for an IM formulation of zuclopenthixol. Prescribing psychotropic drug has to respect good practices including close psychological and somatic monitoring that associates the young patient and his relative (psycho-education program). Particular key-points should be taken into consideration (i.e. pharmacokinetic and physiological specificities, risk of false passage under the age of 6 years with capsules or tablets, presence of alcohol in some oral solution or bitter aroma...). Beside these official data, many studies have been published but must be carefully interpreted according to their level of pertinence. Meta-analysis gather all randomised controlled trials published or not, analyse their specific pertinence and thus provide clinically relevant elements. Randomised controlled trials present clinical interest but key-points in study design must be checked (e.g. number of patients, inclusion and exclusion criteria, length of the study and clinical relevance of clinical scales...). Other studies like open trials or clinical cases do not offersufficient guarantees. Some randomised controlled trials of clinical relevance have been carried out in this population with new pharmacological classes (eg SSRI, atypical antipsychotic drugs) and may lead to extended indications in children and adolescents. According to bibliographic and official data, the main criteria in the prescribing choice may take into consideration the following sis stressing a poor benefit/risk ratio. SSRI may offer better prospects but their use has not been approved in this indication, until now. In OCD, sertraline shows great interest to enhance clinical response and represents the molecule of reference. No drug has been approved for mood disorders in children or adolescent, in France, contrary to USA where lithium can be administered over the age of 12 years. In addition, antiepileptic drugs like carbamazepine or divalproate have conducted to clinical improvement in some studies. Benzodiazepines, hydroxyzine and meprobamate use should be strictly restricted in case of anxiety symptoms but are the only agents approved in this indication despise promising results obtained with SSRI. Transitory insomnia may take advantage of alimemazine prescription (approved use over the age of 36 months). Some typical neuroleptics are indicated in tics or in behaviour disorders associated to autism or related syndromes but present clinical limitations and poor tolerability. Promising clinical trials (randomised or not) have been conducted with new atypical antipsychotic drugs like risperidone. In conclusion, present data available for paediatric use of psychotropic agents emphasizes that safety and effectiveness are not always well established in particular for the treatment of chronic disorders (long term tolerability assessment). Moreover, studies should be carried out to specify factors promoting adherence and quality of life for this young population in order to optimise clinical benefit of drug prescription.
authors.affiliation: Service Pharmacie, EPS de Ville-Evrard, 202, avenue Jean-Jauèbs, 93332 Neuilly-sur-Marne.
authors.forename: G
authors.initials: G
authors.lastname: Dumortier
authors.forename: B
authors.initials: B
authors.lastname: Welniarz
authors.forename: C
authors.initials: C
authors.lastname: Sauvebois
authors.forename: H
authors.initials: H
authors.lastname: Medjdoub
authors.forename: H
authors.initials: H
authors.lastname: Friche
authors.forename: N
authors.initials: N
authors.lastname: Siad
authors.forename: K
authors.initials: K
authors.lastname: Degrassat
mesh_terms: D000293:Adolescent; D002648:Child; D002665:Child Psychiatry / Q000379:methods* / Q000706:statistics & numerical data*; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D006266:Health Education; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D001523:Mental Disorders / Q000188:drug therapy*; D010372:Pediatrics / Q000379:methods* / Q000706:statistics & numerical data*; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000145:classification / Q000493:pharmacokinetics; D014342:Truth Disclosure
chemical_list: D011619:Psychotropic Drugs; D003577:Cytochrome P-450 Enzyme System